loading
Schlusskurs vom Vortag:
$2.11
Offen:
$2.1
24-Stunden-Volumen:
89,044
Relative Volume:
0.55
Marktkapitalisierung:
$78.77M
Einnahmen:
$1.79M
Nettoeinkommen (Verlust:
$-70.90M
KGV:
-0.139
EPS:
-15.54
Netto-Cashflow:
$-34.95M
1W Leistung:
+1.41%
1M Leistung:
-34.74%
6M Leistung:
-44.90%
1J Leistung:
-32.29%
1-Tages-Spanne:
Value
$2.03
$2.18
1-Wochen-Bereich:
Value
$1.90
$2.22
52-Wochen-Spanne:
Value
$1.5201
$16.94

Senti Biosciences Inc Stock (SNTI) Company Profile

Name
Firmenname
Senti Biosciences Inc
Name
Telefon
(650) 382-3281
Name
Adresse
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Name
Mitarbeiter
48
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-16
Name
Neueste SEC-Einreichungen
Name
SNTI's Discussions on Twitter

Vergleichen Sie SNTI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SNTI
Senti Biosciences Inc
2.16 78.77M 1.79M -70.90M -34.95M -15.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-06 Eingeleitet Laidlaw Buy
2022-10-07 Eingeleitet Morgan Stanley Equal-Weight

Senti Biosciences Inc Aktie (SNTI) Neueste Nachrichten

pulisher
Jun 18, 2025

Senti Biosciences Inc (SNTI) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Jun 18, 2025
pulisher
Jun 18, 2025

Senti Bio Receives US FDA Orphan Drug Designation for Potential Blood Cancer Treatment - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Senti Biosciences, Inc. Reports Progress in Phase 1 Trial of SENTI-202 for Acute Myeloid Leukemia, Receives Orphan Drug Designation - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

FDA grants orphan drug designation to Senti Bio’s AML treatment - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Backs Senti Bio Revolutionary Cancer Drug as 60% of AML Patients Face Critical Outcomes - Stock Titan

Jun 18, 2025
pulisher
Jun 13, 2025

Senti Biosciences (NASDAQ:SNTI) Receives Buy Rating from Chardan Capital - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Senti Biosciences (SNTI) Rating and Price Target Updated by Chardan Capital | SNTI Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 09, 2025

Senti Biosciences Announces New Employment Inducement Grants - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

Gene Circuit Pioneer Senti Bio Grants $310K in Stock Options to Expand Next-Gen Therapy Team - Stock Titan

Jun 09, 2025
pulisher
Jun 08, 2025

Laidlaw Initiates Coverage on Senti Biosciences (NASDAQ:SNTI) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jun 07, 2025
pulisher
Jun 07, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc.SNTI - WV News

Jun 07, 2025
pulisher
Jun 07, 2025

SNTI: Senti Biosciences Receives "Buy" Rating from Laidlaw & Co. | SNTI Stock News - GuruFocus

Jun 07, 2025
pulisher
Jun 06, 2025

Laidlaw & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy Recommendation - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

SNTI: Senti Biosciences Receives "Buy" Rating from Laidlaw & Co. - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

Exclusive: Senti Bio Leaders Reveal Next-Gen Cell Therapy Vision in Chardan Fireside Discussion - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target | SNTI Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Laidlaw initiates coverage on Senti Biosciences stock with buy rating By Investing.com - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Laidlaw initiates coverage on Senti Biosciences stock with buy rating - Investing.com

Jun 06, 2025
pulisher
Jun 02, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amerant Bancorp Inc. - GlobeNewswire Inc.

Jun 02, 2025
pulisher
Jun 02, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti ... - Bluefield Daily Telegraph

Jun 02, 2025
pulisher
May 30, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc - ACCESS Newswire

May 30, 2025
pulisher
May 30, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

May 30, 2025
pulisher
May 29, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation Into Senti Biosciences Inc - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise - insights.citeline.com

May 29, 2025
pulisher
May 27, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

May 27, 2025
pulisher
May 26, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

May 26, 2025
pulisher
May 26, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc.GMED - PR Newswire

May 26, 2025
pulisher
May 25, 2025

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 25, 2025
pulisher
May 23, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc - ACCESS Newswire

May 23, 2025
pulisher
May 23, 2025

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar - The Manila Times

May 23, 2025
pulisher
May 22, 2025

Senti Bio CEO Reveals Next-Gen Gene Circuit Platform: Live Webull Biotech Investment Presentation Coming May 29 - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Develo - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Development | SNTI Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Senti Biosciences Receives Additional $1 Million from CIRM to Support Clinical Development of SENTI-202 Cell Therapy - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 - Yahoo Finance

May 22, 2025
pulisher
May 20, 2025

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm - marketscreener.com

May 20, 2025
pulisher
May 16, 2025

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 16, 2025
pulisher
May 09, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc. - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Senti Biosciences advances AML treatment with SENTI-202 trial By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 08, 2025

Senti Biosciences advances AML treatment with SENTI-202 trial - Investing.com

May 08, 2025
pulisher
May 08, 2025

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 - The Manila Times

May 08, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Makes New $181,000 Investment in Senti Biosciences, Inc. (NASDAQ:SNTI) - Defense World

May 07, 2025
pulisher
May 07, 2025

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development - The Manila Times

May 07, 2025
pulisher
May 06, 2025

Senti Biosciences Reports Positive Phase 1 Results for SENTI-202 in Acute Myeloid Leukemia Treatment - Nasdaq

May 06, 2025
pulisher
May 06, 2025

Senti Bio Phase 1 Trial Shows 57% Complete Remission Rate in AML Treatment | SNTI Stock News - Stock Titan

May 06, 2025
pulisher
May 05, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti ... - Bluefield Daily Telegraph

May 05, 2025
pulisher
May 05, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI - FinancialContent

May 05, 2025

Finanzdaten der Senti Biosciences Inc-Aktie (SNTI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Senti Biosciences Inc-Aktie (SNTI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Lu Timothy K
CEO
Feb 06 '25
Sale
4.36
545
2,376
82,082
Rajangam Kanya
Pres. & Chief Med. & Dev. Off.
Feb 04 '25
Sale
4.07
1,297
5,279
8,803
Rajangam Kanya
Pres. & Chief Med. & Dev. Off.
Feb 06 '25
Sale
4.37
182
795
8,621
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Kapitalisierung:     |  Volumen (24h):